OKYO PHARMA LTD (OKYO:NASDAQ)
$1.39 -0.02 (-1.4184%)
Analysed OKYO PHARMA LTD (OKYO:NASDAQ) News Sources
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
28-07-2026
yahoo.com
OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference
08-09-2026
yahoo.com
OKYO Pharma Announces Purchase of Shares by Chief Medical Officer
22-07-2026
yahoo.com
OKYO Pharma Announces Purchase of Shares by Chairman
22-07-2026
yahoo.com
OKYO Pharma Announces Purchase of Shares by Director
23-07-2026
yahoo.com
OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026
09-09-2026
yahoo.com
OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences
29-09-2026
yahoo.com
OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain
06-10-2026
yahoo.com
OKYO Pharma enrolls first patients in Phase 3 trial of neuropathic corneal pain drug
06-10-2026
proactiveinvestors.com
OKYO Pharma Begins Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal Pain
06-10-2026
yahoo.com
What is the current price of OKYO PHARMA LTD (OKYO:NASDAQ)?
The current price of OKYO PHARMA LTD (OKYO:NASDAQ) is $1.39.
OKYO PHARMA LTD (OKYO:NASDAQ) absolute price change since previous trading day?
The absolute price change of OKYO PHARMA LTD (OKYO:NASDAQ) since the previous trading day is $-0.02.
OKYO PHARMA LTD (OKYO:NASDAQ) percentage price change since previous trading day?
The percentage price change of OKYO PHARMA LTD (OKYO:NASDAQ) since the previous trading day is -1.4184%.
What is the most recent average sentiment score for OKYO PHARMA LTD (OKYO:NASDAQ)?
The most recent average sentiment score for OKYO PHARMA LTD (OKYO:NASDAQ) is 68 out of 100.
What is the most recent average sentiment for OKYO PHARMA LTD (OKYO:NASDAQ)?
The most recent sentiment for OKYO PHARMA LTD (OKYO:NASDAQ) is .
SEC-8K** Filing Available For OKYO PHARMA LTD (OKYO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.